Literature DB >> 10823572

Control of occupational hepatitis B among healthcare workers in the Czech Republic, 1982 to 1995.

J Helcl1, J Cástková, C Benes, L Novotna, K A Sepkowitz, J A DeHovitz.   

Abstract

Occupational hepatitis B remains a threat to healthcare workers (HCWs) worldwide, even with availability of an effective vaccine. Despite limited resources for public health, the Czech Republic instituted a mandatory vaccination program for HCWs in 1983. Annual incidence rates of acute hepatitis B were followed prospectively through 1995. Despite giving vaccine intradermally from 1983 to 1989 and intramuscularly as half dose from 1990 to 1995, rates of occupational hepatitis B decreased dramatically, from 177 cases per 100,000 workers in 1982 (before program initiated) to 17 cases per 100,000 in 1995. Among high-risk workers, the effect was even more dramatic (from 587 to 23 per 100,000). We conclude that strong public-health leadership led to control of occupational hepatitis B among HCWs in the Czech Republic, despite limited resources that precluded administering full-dose intramuscular vaccine for much of the program. Application of a similar program should be considered for other countries in regions that currently do not have a hepatitis B vaccination program.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10823572      PMCID: PMC2925678          DOI: 10.1086/501771

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  19 in total

1.  [Antibodies against the superficial component of hepatitis B virus of health workers (author's transl)].

Authors:  K Markvart; F Lobkovic; H Vlasimská; I Pecenková
Journal:  Cesk Epidemiol Mikrobiol Imunol       Date:  1978-11

2.  Inadequate immune response among public safety workers receiving intradermal vaccination against hepatitis B--United States, 1990-1991.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1991-08-23       Impact factor: 17.586

3.  A comparison of the frequency of hepatitis-B antigen and antibody in hospital and nonhospital personnel.

Authors:  T L Lewis; H J Alter; T C Chalmers; P V Holland; R H Purcell; D W Alling; D Young; L D Frenkel; S L Lee; M E Lamson
Journal:  N Engl J Med       Date:  1973-09-27       Impact factor: 91.245

4.  Hepatitis B vaccination program at a New York City hospital: seroprevalence, seroconversion, and declination.

Authors:  J Louther; J Feldman; P Rivera; N Villa; J DeHovitz; K A Sepkowitz
Journal:  Am J Infect Control       Date:  1998-08       Impact factor: 2.918

5.  Reusable needles--a major risk factor for acute virus B hepatitis.

Authors:  M Narendranathan; M Philip
Journal:  Trop Doct       Date:  1993-04       Impact factor: 0.731

6.  Occupational exposure to bloodborne pathogens--OSHA. Final rule.

Authors: 
Journal:  Fed Regist       Date:  1991-12-06

7.  Decline of clinical hepatitis B in workers at a general hospital: relation to increasing vaccine-induced immunity.

Authors:  B P Lanphear; C C Linnemann; C G Cannon; M M DeRonde
Journal:  Clin Infect Dis       Date:  1993-01       Impact factor: 9.079

8.  Impact of the bloodborne pathogens standard on vaccination of healthcare workers with hepatitis B vaccine.

Authors:  T B Agerton; F J Mahoney; L B Polish; C N Shapiro
Journal:  Infect Control Hosp Epidemiol       Date:  1995-05       Impact factor: 3.254

9.  Prevalence and incidence of viral hepatitis in health workers in the prehepatitis B vaccination era.

Authors:  A Gibas; D R Blewett; D A Schoenfeld; J L Dienstag
Journal:  Am J Epidemiol       Date:  1992-09-01       Impact factor: 4.897

Review 10.  Occupational risk of infection with hepatitis B and hepatitis C virus.

Authors:  C N Shapiro
Journal:  Surg Clin North Am       Date:  1995-12       Impact factor: 2.741

View more
  1 in total

1.  Acute hepatitis B in the era of immunisation: pitfalls in the identification of high risk patients.

Authors:  G Rosner; Y Lurie; L Blendis; Z Halpern; R Oren
Journal:  Postgrad Med J       Date:  2006-03       Impact factor: 2.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.